Aurion Biotech has launched its cell therapy Vyznova for serious eye disorder bullous keratopathy in Japan, its debut market, becoming an alternative to corneal replacement using donor tissue.

In September 2024, Aurion announced the first global commercial launch of this technology, Vyznova™ (which includes ... About Aurion Biotech, Inc. Aurion Biotech’s mission is to restore ...

Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive, in the culmination of a months-long struggle for control.

Morningstar brands and products Company Portfolio ...

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed. Aurion will operate as ...

In September 2024, Aurion launched Vyznova™, its first commercial cell therapy product in Japan, for the treatment of bullous keratopathy, a condition that seriously threatens vision. This strategic ...

TOKYO, April 23, 2025--(BUSINESS WIRE)--Aurion Biotech, a clinical-stage regenerative medicine company whose mission is to restore vision to millions of patients, today announced the appointments ...

Key leadership appointments to accelerate global clinical development of AURN001, a transformational cell therapy for corneal endothelial disease Aurion Biotech is developing AURN001, an ...